Martin Shkreli, notoriously known as the “Pharma Bro” who was jailed for almost seven years for defrauding investors, will remain barred from working in the pharmaceutical industry, thanks to a recent decision by an appeals court to uphold a judge’s earlier lifetime ban.
This ruling came from a Manhattan-based federal appeals court that given Shkreli’s history of misconduct, and the “obvious likelihood of its recurrence” along with the “life-threatening nature of its results”, it was justifiable to continue the ban. Additionally, as part of the court’s decision, Shkreli is ordered to pay a significant sum of $64 million over a scheme to manipulate the market for the drug Daraprim.
Shkreli, now 40, and the former Chief Executive Officer of Vyera, had put forth arguments challenging the court ban, but these were dismissed by the court. This legal matter has attracted significant attention for its implications on pharmaceutical governance, regulatory controls, and the limits of executive authority within the industry. As the decision to uphold the ban demonstrates, it sends a strong signal that the judiciary is prepared to take significant measures when malpractice is linked with potential health risks.
Certainly, this ruling marks another chapter in the narrative of Martin Shkreli’s downfall within the industry where he once reigned, and will serve as a legal precedent for those considering similar unlawful ventures.
For further information, please refer to the original report from Bloomberg Law.